PDCD1 and sarcoma: Moving on from the observation that sunitinib is capable of upregulating PD-L1 expression on treated sarcoma cells (Figure 1D) and given its described immunomodulatory properties, we sought to test the hypothesis that PD-1 blockade by nivolumab might be synergistic with sunitinib in the stimulation of T cells.